ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or “RegeneRx”) today announced that it has received an Israeli patent for the treatment of Dry Eye Syndrome using Thymosin beta 4 (Tß4) and various fragments of Tß4, as well as other analogues and derivatives. The patent will expire in 2026.
Help employers find you! Check out all the jobs and post your resume.
